A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
A phase 1/2 trial of Nivolumab in advanced solid tumours, run by Bristol-Myers Squibb, active and no longer recruiting.
Overview
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05888831 by Bristol-Myers Squibb, with 100 participants enrolled, started 2023-06-06 and due to reach its primary completion in 2026-09-30. Interventions recorded: BMS-986449 and Nivolumab.
Similar pages
not linked directly; found by shared links- TrialA Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Shares Bristol Myers Squibb, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Shares Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.